Google DeepMind, Meta and Isomorphic Labs Join $1.8 Billion Virtual Cell Project

Google DeepMind, Meta and Alphabet's AI-powered drug discovery company Isomorphic Labs are joining a major scientific initiative aimed at building a virtual model of human cells.

The companies have committed a combined $300 million to the Biohub-led Virtual Biology Initiative, a broader project valued at approximately $1.8 billion when funding, data, computing resources and measurement technology are included. The effort also involves the U.S. Department of Energy and the National Institutes of Health.

What Is the Virtual Cell Project?

The ambitious project aims to create AI models capable of predicting how cells respond under different biological conditions.

Instead of relying exclusively on physical laboratory experiments, researchers hope to eventually use these models to conduct certain experiments digitally. Scientists could potentially test how cells respond to diseases, drugs or other biological changes before carrying out expensive and time-consuming laboratory work.

The goal is not to create a consumer product. Building a reliable virtual cell is expected to require years of research and enormous amounts of biological data.

Google DeepMind, Meta and Isomorphic Labs Invest $300 Million

Google DeepMind, Meta and Isomorphic Labs will collectively contribute $300 million to the initiative.

Biohub, the nonprofit organization founded by Mark Zuckerberg and Priscilla Chan, had already committed $500 million to the project. The U.S. Department of Energy is expected to contribute more than $500 million over five years, while the NIH will provide biological datasets, repositories and research resources developed through previous federal investments.

Together, these contributions bring the initiative's stated overall value to around $1.8 billion.

Why Biological Data Is So Important

Artificial intelligence models are only as useful as the data used to train them.

The Virtual Biology Initiative plans to generate large quantities of biological measurements by studying how cells react to many different conditions. That information can then be used to train AI systems capable of making predictions about cellular behavior.

Researchers hope this approach can help answer biological questions that would otherwise require huge numbers of laboratory experiments.

The first major dataset is expected in roughly one year, while functional predictive models are being targeted over a period of about five years.

How AI Could Change Drug Discovery

One of the biggest potential applications is pharmaceutical research.

Developing a new medicine can take years and require enormous investments. Scientists must identify promising targets, design candidate molecules, test them in laboratory environments and eventually conduct clinical trials.

A sufficiently accurate AI model of biological systems could help researchers narrow down promising candidates before moving to physical experiments.

That does not mean AI will replace laboratories or clinical trials. Instead, the technology could help scientists prioritize experiments and reduce the number of less promising candidates that need to be tested.

Isomorphic Labs is particularly relevant to this effort because the company focuses on applying AI to drug discovery. It was established as an Alphabet company with the goal of using AI to transform the drug development process.

Isomorphic Labs Is Already Investing Heavily in AI Drug Discovery

The new initiative comes as Isomorphic Labs continues expanding its own AI drug-development efforts.

In May 2026, Isomorphic Labs announced a $2.1 billion Series B funding round. The company said the money would be used to develop its AI drug design engine, expand its operations and advance drug candidates toward clinical development.

The company's involvement in the Virtual Biology Initiative could therefore provide additional biological data and infrastructure that complement its existing AI drug discovery work.

Commercial Partners Will Get Early Access to Some Data

One important aspect of the project is how the newly generated data will be distributed.

Commercial partners contributing to certain datasets are expected to receive approximately one year of exclusive access before that data becomes publicly available. Government-funded datasets can have different access arrangements.

The approach is intended to encourage private companies to invest in large-scale biological research while eventually making the resulting scientific resources more broadly available.

However, the temporary access period also raises questions about whether researchers outside the participating companies will have to wait before gaining access to some of the most valuable datasets.

Meta's Role Goes Beyond Funding

Meta's involvement is particularly notable because the company is not primarily known for pharmaceutical research.

The company's connection to the project comes through Biohub, which was founded by Mark Zuckerberg and Priscilla Chan. Meta also brings significant AI infrastructure and expertise to the partnership.

For Meta, the initiative represents another opportunity to explore how large-scale AI systems can be applied to scientific research beyond traditional consumer applications.

DeepMind Brings Experience in AI and Biology

Google DeepMind has already demonstrated the potential of AI in biological research through systems such as AlphaFold, which transformed the prediction of protein structures.

DeepMind and Isomorphic Labs have also continued exploring AI applications in biology, drug design and biosecurity. Google DeepMind says technologies such as AlphaFold, AlphaGenome and Isomorphic Labs' drug design systems could help researchers understand biological systems and accelerate medical research.

The virtual cell initiative takes that idea a step further by attempting to model cellular behavior rather than focusing on a single biological problem.

A Five-Year Test for AI-Powered Biology

The project's five-year target will be an important measure of whether the ambitious idea can become practical.

Creating a virtual cell that accurately predicts biological behavior is considerably more difficult than building an AI system that generates text or images. Biology involves enormous numbers of interacting processes, and small changes can produce unpredictable results.

For that reason, the initiative's supporters are treating the virtual cell as a long-term scientific challenge rather than an immediate commercial product.

If successful, however, the technology could give researchers a powerful new way to investigate disease and evaluate potential treatments.

What This Means for the Future of AI

The partnership between Google DeepMind, Meta, Isomorphic Labs and government research organizations highlights a growing trend: major AI companies are increasingly turning their attention toward scientific and biological applications.

The next major AI breakthroughs may not be limited to chatbots and consumer software. AI models capable of understanding biology could eventually influence drug discovery, disease research and medical development.

For now, the virtual cell remains a long-term goal. But with billions of dollars in combined resources and some of the world's largest technology and research organizations involved, the project could become one of the most significant experiments in AI-powered biology.